<DOC>
	<DOCNO>NCT02661958</DOCNO>
	<brief_summary>The purpose study evaluate superiority efficacy assess safety tolerability product S6G5T-3 S6G5T-1 compare respective active component vehicle treatment acne .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability S6G5T-1 S6G5T-3 Treatment Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Male female subject 9 year age old . 2 . In good general health Based medical record 3 . Have diagnosis facial acne &gt; 25 &lt; 100 noninflammatory lesion &gt; 20 &lt; 50 inflammatory lesion . 4 . Have score `` 3 '' `` 4 '' ( Moderate Severe ) IGA scale . 5 . Have two few cyst nodule ( defined inflammatory lesion great equal 5 mm diameter ) . 6 . Sexually active woman childbearing potential must use one follow birth control option : One highly effective contraception method : . Intrauterine device ( IUD ) ; ii . Hormonal , least 3 month ( Pills , injection , implant , transdermal patch , vaginal ring ) ; iii . Tubal ligation ; iv . Partner vasectomy , 7 . OR A barrier form contraception ( list ) . Male female condom ; ii . Diaphragm spermicides ; iii . Cervical cap spermicide ; iv . Contraceptive sponge 8 . Willingness capacity protocol compliance ( subject age consent , parent/guardian must willing able comply study requirement ) . 9 . Male subject must cleanshaven agree remain study visit . 10 . Consent participate , verify sign approve write Informed Consent Form HIPAA ; subject age consent , sign assent form sign Informed Consent Form parent/guardian require accordance local federal regulation . 1 . More two acne nodule cyst ( defined inflammatory lesion great equal 5 mm diameter ) 2 . Acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc severe acne require systemic treatment . 3 . Underlying disease require use interfere topical systemic therapy . 4 . Other dermatological condition require use interfering topical systemic therapy might interfere study assessment , limited , atopic dermatitis , perioral dermatitis , rosacea . 5 . Beard , facial hair , tattoo may interfere study assessment . 6 . Use tan booth tan lamp within one week prior Baseline unwillingness refrain use study . 7 . Use hormonal contraceptive , unless subject stable dose least three month prior enrollment . 8 . Use hormonal contraceptive solely control acne . 9 . Use prohibit medication prior study unwillingness refrain use study . 10 . Known sensitivity study drug ingredient . Allergy benzoyl peroxide , tretinoin , parabens glycerin ingredient list investigator brochure . 11 . Clinically significant abnormal finding condition ( acne ) , might , opinion investigator , interfere study evaluation pose risk subject safety study . 12 . Female subject pregnant and/or nursing planning become pregnant course trial . Subjects test positive pregnancy start test treatment discontinue test treatment follow safety purpose . 13 . Participation another investigational drug device research study within 30 day enrollment five halflives drug , whichever longer . 14 . Current history facial skin cancer . 15 . Is employee family member study investigator study staff direct involvement propose study . 16 . Is family member study participant recruit enrol propose study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>acne vulgaris</keyword>
	<keyword>acne</keyword>
</DOC>